> Detailanzeige

Morales-Avalos, Rodolfo; Ramos-Morales, Tomas; García-Pedro, Jesús A.; Espinoza-Galindo, Ana M.; Acosta-Olivo, Carlos; Morcos-Sandino, Michelle; Silva-Ramos, Héctor N.G.; Peña-Martínez, Víctor M.; Rodríguez-Torres, Raymundo A.; Vilchez-Cavazos, Félix

Tranexamic acid versus aminocapróic acid in multiple doses via the oral route for the reduction of postoperative bleeding in total primary hip arthroplasty: a prospective, randomized, double-blind, controlled study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Tranexamic acid versus aminocapróic acid in multiple doses via the oral route for the reduction of postoperative bleeding in total primary hip arthroplasty: a prospective, randomized, double-blind, controlled study
  • Beteiligte: Morales-Avalos, Rodolfo; Ramos-Morales, Tomas; García-Pedro, Jesús A.; Espinoza-Galindo, Ana M.; Acosta-Olivo, Carlos; Morcos-Sandino, Michelle; Silva-Ramos, Héctor N.G.; Peña-Martínez, Víctor M.; Rodríguez-Torres, Raymundo A.; Vilchez-Cavazos, Félix
  • Erschienen: Ovid Technologies (Wolters Kluwer Health), 2021
  • Erschienen in: Blood Coagulation & Fibrinolysis, 32 (2021) 2, Seite 132-139
  • Sprache: Englisch
  • DOI: 10.1097/mbc.0000000000001005
  • ISSN: 0957-5235; 1473-5733
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: To compare the effects of oral ε-aminocaproic acid (EACA) as a hemostatic agent versus the use of oral tranexamic acid (TXA) administered in multiple doses pre and postsurgery in patients undergoing elective primary total hip arthroplasty (THA). We enrolled 102 patients that were randomly divided into two groups: received three oral doses of EACA (2000 mg per dose) or three oral doses of TXA (1300 mg per dose). The medication was given according to the following schedule: 2 h before surgery and 6 and 12 h after surgery. The variables analyzed to compare the effectiveness of the hemostatic agents were total blood loss, hidden blood loss, external blood loss, transfusion rate, intraoperative blood loss, decreases in hemoglobin and hematocrit values, surgical drainage output, visual analog scale, and surgical complications. There were no significant differences between any of the study variables for the group receiving oral TXA and the group receiving oral EACA (P > 0.05). Our study showed that the use of oral EACA was similar to its counterpart TXA regarding the evaluated parameters. TXA did not have superior blood conservation effects, safety profile, or differences in functional scales compared with EACA in THA. We consider the use of multiple oral doses of aminocaproic acid at the selected dose to be effective as a standard protocol to achieve less blood loss and a lower rate of transfusion and adverse events related to the medication in patients undergoing a THA.